JP2024500360A - 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法 - Google Patents

関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法 Download PDF

Info

Publication number
JP2024500360A
JP2024500360A JP2023535468A JP2023535468A JP2024500360A JP 2024500360 A JP2024500360 A JP 2024500360A JP 2023535468 A JP2023535468 A JP 2023535468A JP 2023535468 A JP2023535468 A JP 2023535468A JP 2024500360 A JP2024500360 A JP 2024500360A
Authority
JP
Japan
Prior art keywords
seq
polymersomes
population
poly
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500360A5 (https=
JPWO2022123070A5 (https=
Inventor
マドハバン ナラニ
ジャン ハン ラム
ファビアン デカイヨ
トーマス アンドリュー コーネル
アミット クマル カーン
Original Assignee
エイシーエム バイオラブズ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイシーエム バイオラブズ プライベート リミテッド filed Critical エイシーエム バイオラブズ プライベート リミテッド
Publication of JP2024500360A publication Critical patent/JP2024500360A/ja
Publication of JP2024500360A5 publication Critical patent/JP2024500360A5/ja
Publication of JPWO2022123070A5 publication Critical patent/JPWO2022123070A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023535468A 2020-12-11 2021-12-13 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法 Pending JP2024500360A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20213488.8 2020-12-11
EP20213488 2020-12-11
PCT/EP2021/085366 WO2022123070A1 (en) 2020-12-11 2021-12-13 Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant

Publications (3)

Publication Number Publication Date
JP2024500360A true JP2024500360A (ja) 2024-01-09
JP2024500360A5 JP2024500360A5 (https=) 2024-07-11
JPWO2022123070A5 JPWO2022123070A5 (https=) 2024-07-11

Family

ID=74187071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535468A Pending JP2024500360A (ja) 2020-12-11 2021-12-13 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法

Country Status (6)

Country Link
US (1) US20230398207A1 (https=)
EP (1) EP4259197A1 (https=)
JP (1) JP2024500360A (https=)
AU (1) AU2021396659A1 (https=)
CA (1) CA3193643A1 (https=)
WO (1) WO2022123070A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704135QA (en) * 2012-11-19 2017-06-29 Agency Science Tech & Res Method For Eliciting An Immune Response To An Immunogen
EP4604997A2 (en) * 2022-10-21 2025-08-27 PDS Biotechnology Corporation Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145475A2 (en) * 2018-01-25 2019-08-01 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
JP2020007341A (ja) * 2013-09-19 2020-01-16 ゾエティス・サービシーズ・エルエルシー 油性アジュバント

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
EP2281033B1 (en) 2008-04-17 2014-10-15 Vin de Bona Trading Co Pte Post release modification of viral envelopes
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
CN102460150B (zh) 2009-04-20 2015-05-20 新加坡科技研究局 囊泡系统及其用途
EP2601262A4 (en) 2010-08-05 2014-01-22 Agency Science Tech & Res VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION
CA2866170A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
DK2906717T3 (en) 2012-10-11 2019-04-01 Vin De Bona Trading Company Pte Ltd PROCEDURE FOR PAINTING MICROVESICS
SG10201704135QA (en) 2012-11-19 2017-06-29 Agency Science Tech & Res Method For Eliciting An Immune Response To An Immunogen
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
US10696985B1 (en) * 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
CN114502191B (zh) * 2019-08-01 2026-04-03 Acm生物实验室私人有限公司 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物
US20230256082A1 (en) * 2020-04-24 2023-08-17 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020007341A (ja) * 2013-09-19 2020-01-16 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
WO2019145475A2 (en) * 2018-01-25 2019-08-01 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof

Also Published As

Publication number Publication date
EP4259197A1 (en) 2023-10-18
AU2021396659A9 (en) 2023-07-13
AU2021396659A1 (en) 2023-05-04
US20230398207A1 (en) 2023-12-14
CA3193643A1 (en) 2022-06-16
WO2022123070A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
JP7676030B2 (ja) 関連づけられた抗原を有するポリマーソームの集団を、関連づけられたアジュバントを有するポリマーソームの集団と一緒に投与することによって、免疫応答を誘発する方法、およびそれら２つのポリマーソーム集団を含む組成物
JP7542257B2 (ja) 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
JP2024500360A (ja) 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
US20230256082A1 (en) Vaccine against human-pathogenic coronaviruses
US20250281405A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
EP4288033B1 (en) Polymersome associated adjuvant for use in stimulating an immune response
EP3849600A1 (en) Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
Pho Surface Engineering of Protein Nanoparticles for Intranasal Delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260326